By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medical Device Network on MSN2d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monogram Orthopaedics Inc (MGRM – Research ...
Short interest in Vivani Medical Inc (NASDAQ:VANI) decreased during the last reporting period, falling from 300.99K to 279.35K. This put 0.82% of the company's publicly available shares short.
About Cortigent, Inc. Cortigent, Inc., formerly Second Sight Medical Products and a wholly owned subsidiary of Vivani, is developing brain implant devices to help people recover critical body ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback